Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis

L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby

doi:10.1128/AAC.00171-15

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis

Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.

Authors

L Davies Forsman¹, C G Giske², J Bruchfeld³, T Schön⁴, P Juréen⁵, K Ängeby⁶

Affiliations

¹ Unit of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden [email protected].
² Department of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
³ Unit of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden.
⁴ Department of Medical Microbiology, Linköping University Hospital, Linköping, Sweden Department of Clinical Microbiology and Infectious Diseases, Kalmar County Hospital, Kalmar, Sweden.
⁵ Unit of Highly Pathogenic Bacteria, Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
⁶ Department of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden Department of Microbiology, The University of the West Indies, Kingston, Jamaica.

Abstract

We investigated the activity of meropenem-clavulanic acid (MEM-CLA) against 68 Mycobacterium tuberculosis isolates. We included predominantly multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) isolates, since the activity of MEM-CLA for resistant isolates has previously not been studied extensively. Using Middlebrook 7H10 medium, all but four isolates showed an MIC distribution of 0.125 to 2 mg/liter for MEM-CLA, below the non-species-related breakpoint for MEM of 2 mg/liter defined by EUCAST. MEM-CLA is a potential treatment option for MDR/XDR-TB.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antitubercular Agents / pharmacology*
Clavulanic Acid / pharmacology*
Meropenem
Microbial Sensitivity Tests
Mycobacterium tuberculosis / drug effects*
Thienamycins / pharmacology*
Tuberculosis, Multidrug-Resistant / microbiology

Substances

Antitubercular Agents
Thienamycins
Clavulanic Acid
Meropenem